Giredestrant plus palbociclib vs anastrozole plus palbociclib for post-menopausal, HER2-negative, untreated early breast cancer

ESMO President: What to watch for at ESMO 2021

Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or carfilzomib in RRMM patients

Patterns of recurrence after a radical nephroureterectomy in high-risk upper tract urothelial carcinoma

Breast cancer roundup from ASCO 2021

Highlights from ASCO 2021

NIVO plus chemo vs chemo alone as neoadjuvant treatment for patients with resectable NSCLC

Olaparib improves disease-free survival in high-risk early-stage HER2-negative breast cancer with BRCA 1/2 mutations

KEYNOTE-564: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma

Changes in cancer patient management in India during the pandemic

ERAS in gynaecological oncology from developed to developing countries

SEMS trial: result of a prospective, multi-institutional phase II clinical trial of surgery in early metastatic seminoma